Testing the drug M3554 in people with advanced soft tissue sarcoma or glioblastoma
Official title: Anti-GD2 ADC M3554 in Advanced Solid Tumors
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study is testing a drug called M3554 to find the right dose and to watch for side effects.
Read our full plain-language summary
What the trial team says
The purpose of this study is to establish the recommended doses and further evaluate the safety and preliminary antitumor activity of M3554 in participants with soft tissue sarcoma (STS) and glioblastoma, IDH-wildtype. Study details include: Study Duration per participant: Approximately 4 months
Key facts
- Registry number
- NCT06641908
- Stage of testing
- Phase 1
- Conditions studied
- Advanced Solid Tumor
Where it is running
This trial lists 11 sites.
-
Belgium
- UZ Leuven (Leuven)
-
France
- Institut Bergonié - Service d'Oncologie Médicale (Bordeaux)
- Centre Oscar Lambret - cancerologie generale (Lille)
- Centre Leon Berard - Service d'Oncologie Medicale (Lyon)
- Centre Antoine Lacassagne - Service d'Hématologie Oncologie (Nice)
-
Japan
- National Cancer Center Hospital (Chūōku)
-
Massachusetts
- Dana-Farber Cancer Institute (Boston)
-
New York
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York - Memorial Sloan Kettering Cancer Center (CC)- Westc (New York)
-
Surrey
- Royal Marsden Hospital-Sutton - Dept of Oncology (Surrey) (Sutton)
-
Switzerland
- Universitaetsspital Zuerich - Klinik fuer Neurologie (Zurich)
-
Texas
- The University of Texas MD Anderson Cancer Center (Houston)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.